Related Experiment Video
Updated: Aug 22, 2025
Microfluidic Device for Recreating a Tumor Microenvironment in Vitro
Published on: November 20, 2011
Microfluidic technologies in tumour metabolism
Meabh Doherty1, Tongchuan Wang1, Dimitrios A Lamprou1
1School of Pharmacy, Queens University Belfast, Lisburn Road, Belfast BT9 7BL, UK.
Abstract:
The tumour microenvironment presents many challenges in the development and evaluation of new anti-cancer therapeutics. Enhanced understanding of the unique metabolic characteristics of cancer cells could provide valuable knowledge to develop broad-spectrum anti-neoplastic agents with reduced systemic toxicity. However, a major limitation is the lack of physiological relevance of many conventional in vitro models. Emerging microfluidic platform technologies, hold the potential of recapitulating the physiological and pathological features of the tumour microenvironment, thus increasing the relevance of pre-clinical experimental data. With precise manipulation of physical and chemical properties, the microfluidic based, tumour-on-chip authentically replicates the tumour growth environment, potentially helping accelerate the pre-clinical screening of novel anti-tumour drug combinations. Additionally, nanoscale vehicles produced using microfluidic technologies, offer an emerging solution to modulate the hydrophilicity and release kinetics of drugs that in the free state exhibit challenging pharmacokinetics. This article will review the current state-of-the-art in this space and outline important challenges that are yet to be overcome.
Insights
Microfluidic "tumor-on-chip" platforms enhance anti-cancer drug development by mimicking the tumor microenvironment. These advanced models improve pre-clinical testing and enable novel drug delivery systems for reduced toxicity.
Area of Science:
- Biomedical Engineering
- Cancer Therapeutics
- Drug Development
Background:
- The tumor microenvironment poses significant challenges for anti-cancer drug development.
- Conventional in vitro models often lack the physiological relevance needed for accurate pre-clinical evaluation.
- Understanding cancer cell metabolism is key to developing effective and less toxic anti-neoplastic agents.
Purpose of the Study:
- To review the current state-of-the-art of microfluidic technologies in cancer research.
- To highlight the potential of microfluidic platforms for improving pre-clinical anti-cancer drug screening.
- To discuss the application of microfluidics in developing advanced drug delivery systems.
Main Methods:
- Review of emerging microfluidic platform technologies for recapitulating tumor microenvironment features.
- Analysis of "tumor-on-chip" systems for authentic replication of tumor growth environments.
- Exploration of microfluidic applications in creating nanoscale drug delivery vehicles.
Main Results:
- Microfluidic platforms offer enhanced physiological relevance compared to conventional models.
- Tumor-on-chip systems can accelerate the pre-clinical screening of anti-tumor drug combinations.
- Microfluidic technologies enable the development of nanoscale vehicles for improved drug pharmacokinetics.
Conclusions:
- Microfluidic technologies hold significant promise for advancing cancer therapeutics development.
- These platforms can increase the translational relevance of pre-clinical data.
- Further research is needed to overcome existing challenges in microfluidic applications for oncology.
More Related Videos
05:44Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma
Published on: November 5, 2020
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
